iSERA Lifesciences Limited has approved its standalone audited financial results for the quarter and year ended March 31, 2026. The Board of Directors met on May 21, 2026, to consider and approve the results, which were reviewed by the audit committee. The statutory auditor, GMKS & Co., issued an audit report with an unmodified opinion for the period.

The company reported a revenue from operations of INR 135.50 lakh for the year ended March 31, 2026, compared to INR 26.52 lakh in the previous year. Total income for the year stood at INR 142.52 lakh. The company posted a profit for the year of INR 25.94 lakh, a significant increase from the profit of INR 11.81 lakh in the prior year. Earnings per share (EPS) for the year were recorded at INR 0.74 on a basic and diluted basis.

Financial Performance

The company’s expenses for the year totaled INR 108.88 lakh. Direct expenses accounted for INR 45.00 lakh, while employee benefits expense was INR 5.25 lakh. Other expenses, which include right issue expenses of INR 42.25 lakh, amounted to INR 58.63 lakh. The finance costs were nil for the period.

Capital Structure and Rights Issue

During the year, the company allotted 80,85,550 equity shares of face value INR 10 each at par, pursuant to a rights issue aggregating to INR 8,08,55,500. The shares were issued in the ratio of 25 equity shares for every 1 fully paid-up equity share held. The issued, subscribed, and paid-up equity share capital as of March 31, 2026, stood at INR 840.90 lakh, comprising 84,08,972 equity shares.

The company’s net worth and paid-up equity share capital were below the thresholds of INR 10 crore and INR 25 crore respectively as of March 31, 2025. Consequently, the company is exempt from complying with certain corporate governance requirements specified in SEBI (LODR) Regulations, 2015.

iSERA Lifesciences Limited (formerly known as Covidh Technologies Limited) has submitted newspaper advertisements for its postal ballot notice to BSE Limited in compliance with regulatory requirements. The submission was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Postal Ballot Process Details

The company has initiated a postal ballot process for seeking member approval on specified resolutions. The postal ballot notice dated April 21, 2026 has been circulated to all members of the company for their consideration and voting.

Publication and Accessibility

The postal ballot notice advertisement has been published in leading newspapers to ensure wide dissemination among stakeholders. The company has chosen both English and regional language publications for comprehensive coverage.

Published in:

• Financial Express – April 22, 2026
• Loksatta – April 22, 2026

The postal ballot notice is also accessible on the company's official website at www.covidhtechnologies.com , providing digital access to shareholders and other interested parties.

Company Information

iSERA Lifesciences Limited operates under CIN L72200PN1993PLC252720 and trades with scrip code 534920. The company's registered office is located at Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001.

Regulatory Compliance

The submission demonstrates the company's adherence to regulatory disclosure requirements under SEBI listing regulations. Company Secretary and Compliance Officer Deepakshi, with membership number A76335, has digitally signed the communication to BSE on April 22, 2026 at 13:16:03 +05'30'.

The remote e-voting facility provides shareholders with a convenient mechanism to participate in the decision-making process during the specified voting period extending until May 21, 2026.